Stock CALTX CALLIDITAS THERAPEUTICS AB
Add to a list
To use this feature you must be a member
Log inSign up

Other languages Calliditas Therapeutics AB

Equities

CALTX

SE0010441584

Real-time Estimate Cboe Europe
Other stock markets
 05:12:00 2024-05-17 am EDT 		5-day change 1st Jan Change
116.4 SEK -0.56% Intraday chart for Calliditas Therapeutics AB +4.24% -9.13%
May. 16 European Equities Traded in the US as American Depositary Receipts Trend Lower in Thursday Trading MT
May. 15 European Equities Traded in the US as American Depositary Receipts Nudge Higher in Wednesday Trading MT

Other languages

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
European Equities Traded in the US as American Depositary Receipts Trend Lower in Thursday Trading
European Equities Traded in the US as American Depositary Receipts Nudge Higher in Wednesday Trading
European Equities Traded in the US as American Depositary Receipts Nudge Higher in Tuesday Trading
Calliditas Therapeutics Partner Offers Nefecon in China; Shares Rise
European Equities Traded in the US as American Depositary Receipts Trend Modestly Higher in Wednesday Trading
Calliditas Therapeutics AB Announces Positive Topline Results of Phase 2 Head and Neck Cancer Trial with Lead NOX Inhibitor Candidate, Setanaxib
European Equities Traded in the US as American Depositary Receipts Rise Modestly Higher in Thursday Trading
European Equities Traded in the US as American Depositary Receipts Trend Modestly Higher in Thursday Trading
Calliditas Therapeutics Says OLE Study Shows Treatment Response Consistent With Late-Stage NefIgArd Study's Findings
Calliditas Therapeutics AB Announces Positive NefIgArd Open Label Extension Results
European Equities Traded in the US as American Depositary Receipts Rebound in Monday Trading
European Equities Traded in the US as American Depositary Receipts Trend Higher in Friday Trading But End Week Down
Calliditas Therapeutics Presents Additional Data Analyses from the Phase 3 NeflgArd trial of Nefecon in Primary IgA Nephropathy at the ISN World Congress of Nephrology 2024
Calliditas Therapeutics AB Presents Additional Data Analyses from the Phase 3 NeflgArd Trial of Nefecon in Primary IgA Nephropathy at the ISN World Congress of Nephrology 2024
European Equities Traded in the US as American Depositary Receipts Trend Lower in Wednesday Trading
European Equities Traded in the US as American Depositary Receipts Start Week Higher in Monday Trading
European Equities Traded in the US as American Depositary Receipts Lower in Friday Trading
European Equities Traded in the US as American Depositary Receipts Decline in Thursday Trading
European Equities Traded in the US as American Depositary Receipts Trend Lower in Wednesday Trading
European Equities Traded in the US as American Depositary Receipts Trend Lower in Tuesday Trading
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. CALTX Stock
  4. News Calliditas Therapeutics AB
  5. Other languages
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
BENEFIT NOW